Ladder Bio
Focus: Ladder Bio is a public biotechnology company focused on developing spiroligomers, a novel molecular platform, for oncology indications. The company is early-stage with no approved products or clinical programs currently disclosed.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Ladder Bio?
AI assessmentLadder Bio offers an early-stage platform bet in oncology with public-company stability, but the absence of clinical programs and active hiring suggests limited near-term career development momentum.
Why Work Here
- Access to proprietary spiroligomer technology platform with potential to unlock new oncology mechanisms
- Public company status provides liquidity and equity upside with less dilution risk than private biotech
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (1)
Interview Prep Quick Facts
Help build intelligence for Ladder Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.